ECM
RYTM icon

Endurant Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Endurant Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-105,792
Closed -$1.22M – 73
2022
Q1 		$1.22M Sell
105,792
-91,670
-46% -$805K 0.32% 50
2021
Q4 		$1.97M Buy
+197,462
New +$2.22M 0.48% 41

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Endurant Capital Management's RYTM Position: Q2 2022 in Review

Endurant Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2022, closing a stake of 105,792 shares — an estimated $1.22M sold.

Endurant Capital Management first reported a position in RYTM in Q4 2021 and held it in 2 quarters. The position peaked at $1.97M in Q4 2021. 90 funds tracked by Wall St. Rank hold RYTM as of Q2 2022.

  • Endurant Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Endurant Capital Management sold 105,792 Rhythm Pharmaceuticals shares in Q2 2022, an estimated $1.22M.
  • Endurant Capital Management first reported a position in Rhythm Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Endurant Capital Management's Rhythm Pharmaceuticals position peaked at $1.97M in Q4 2021.
  • 90 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2022.

Based on Endurant Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.